Market Cap | 358.19M | P/E | - | EPS this Y | -14.80% | Ern Qtrly Grth | - |
Income | -93.14M | Forward P/E | -3.31 | EPS next Y | 150.30% | 50D Avg Chg | -13.00% |
Sales | 8.12M | PEG | 0.38 | EPS past 5Y | - | 200D Avg Chg | -10.00% |
Dividend | N/A | Price/Book | 3.25 | EPS next 5Y | -6.40% | 52W High Chg | -48.00% |
Recommedations | 1.80 | Quick Ratio | 2.24 | Shares Outstanding | 77.18M | 52W Low Chg | 26.00% |
Insider Own | 24.25% | ROA | -36.66% | Shares Float | 25.09M | Beta | 1.29 |
Inst Own | 53.91% | ROE | -91.51% | Shares Shorted/Prior | 1.95M/1.77M | Price | 6.02 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 139,854 | Target Price | 20.60 |
Oper. Margin | -16,279.79% | Earnings Date | Nov 12 | Volume | 67,695 | Change | -0.82% |
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
RBC Capital | Outperform | Aug 13, 24 |
Chardan Capital | Buy | Jul 31, 24 |
RBC Capital | Outperform | Mar 15, 24 |
RBC Capital | Outperform | Aug 11, 23 |
Chardan Capital | Buy | Aug 11, 23 |
Piper Sandler | Overweight | May 12, 23 |
Chardan Capital | Buy | Mar 16, 23 |
RBC Capital | Outperform | Mar 15, 23 |
Chardan Capital | Buy | Aug 12, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
PERCEPTIVE ADVISORS LLC | Director Director | May 05 | Buy | 5.75 | 4,347,826 | 25,000,000 | 11,281,103 | 05/15/23 |
Zeldin Robert K | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Jun 03 | Buy | 7.9 | 5,000 | 39,500 | 5,000 | 06/06/22 |
Forbes Alexandria | President and CEO President and CEO | Nov 16 | Sell | 20.07 | 30,000 | 602,100 | 1,080,781 | 11/18/21 |
Giroux Richard | CFO & COO CFO & COO | Oct 19 | Sell | 20.76 | 22,000 | 456,720 | 819,218 | 10/21/21 |
Forbes Alexandria | President and CEO President and CEO | Oct 18 | Sell | 17.57 | 30,000 | 527,100 | 1,110,781 | 10/20/21 |